ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.

ABP-102/CT-P72 在HER2高表达的乳腺癌和胃癌模型中展现出强效的细胞毒性，同时在HER2低表达细胞中显著降低活性，从而克服了以往HER2靶向T细胞引导剂的一项关键局限性[1]。
与HER2 x CD3双特异性抗体的标杆药物runimotamab的生物类似物相比，ABP-102/CT-P72的肿瘤抑制效果提高了多达两倍[1]。
通过对CD3进行功能性单价工程改造，ABP-102/CT-P72在HER2低表达模型中显著减少了细胞因子释放，同时在HER2高表达模型中仍保持强效的细胞毒性[1]。

在食蟹猴的剂量递增研究中，ABP-102/CT-P72即使在剂量超过母抗体最大耐受剂量180倍的情况下也未出现明显毒性[1]。